



Pharmacogenetics role of dihydropyrimidine dehydrogenase and thymidylate synthase genes in fluoropyrimidine-based chemotherapy.

Mohamad Hadi Abasian¹, Nafiseh Ansarinejad ^{2,3}, Bahareh Abbasi ^{3,4}, Tayeb Ramim³ and Ali M. Ardekani⁵

1. Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

2. Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran

3. Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, IR Iran

4 . Department of Medical Genetic, Medical Biotechnology Ins., National Institute of Genetic Engineering and iotechnology (NIGEB), Tehran, IR Iran

5. Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, University of Tehran, Tehran, Iran (iranhealth@hotmail.com)

Abstract

Introduction & Aim: The fluoropyrimidine drug 5-fluorouracil (5-FU) and the prodrug capecitabine, have been extensively used for treatment of many types of cancer including colorectal, gastric and head and neck. Approximately 10% of the patients suffer from severe fluoropyrimidine-induced toxicity, like diarrhea, mucositis, myelosuppression and hand-foot syndrome. This may lead to dose reduction and treatment discontinuation. Pharmacogenetics research could be useful for identification of predictive markers in chemotherapy treatment.

Methods: Germline DNA was extracted from 83 cancer patients treated with fluoropyrimidine-based chemotherapy. In this study, we genotyped three polymorphisms in dihydropyrimidine dehydrogenase gene (rs3918290),(rs67376798),(rs55886062) and two polymorphisms, The variable number of tandem repeat (VNTR) polymorphism (rs45445694) and 6-bp insertion/deletion polymorphism(rs151264360) in thymidylate synthase gene. These genetic markers were correlated with toxicity to treatment. 5-FU-related toxicities such as Anemia, febrile neutropenia, neurotoxicity, vomiting, nausea and mucositis were evaluated according to NCI-CTC criteria version 4.0.

Results: DPYD gene polymorphisms was not observed in this study. The frequency of the TYMS +6 bp allele was 40.35% and the -6 bp allele was



59.65% in this study. And frequency of VNTR 2R allele was 48.75% and 3R allele was 51.15%. Toxicity grade two diarrhea, mucositis, nausea, vomiting and neurotoxicity are 2.2%, 24.1%, 15.7%, 6% and 51.8%, respectively. Thymidylate synthase ins/del polymorphisms was significantly associated with increased grade three Neurotoxicity ($p=0.02$).

Conclusion: A pharmacogenetic approach could be a useful strategy for personalizing chemotherapy in cancer patients. Although rare DPYD polymorphisms was not observed in our study, according to large population studies, DPYD gene polymorphisms could be used as a predictive biomarker for efficacy of fluoropyrimidine-based chemotherapy.

Key words: Chemotherapy, Fluoropyrimidines, 5-fluorouracil, Colorectal cancer, Gastric cancer, Dihydropyrimidine dehydrogenase, Pharmacogenetics